AvenCell raised $112 million in a Series B funding round led by Novo Holdings to accelerate clinical validation of its proprietary Universal Switchable CAR-T cell therapy platform.
NYBC VenturesF Prime CapitalEight Roads Ventures JapanPiper Heartland Healthcare CapitalBlackstone Life SciencesNovo Holdings
Description
AvenCell Therapeutics, Inc. has successfully raised $112 million in its Series B financing round. The funding, led by Novo Holdings and joined by new investors such as F-Prime Capital and Eight Roads Ventures Japan, will support the clinical development of its innovative CAR-T cell therapy platform.
Who to call at AvenCell Therapeutics, and when
A new round usually means AvenCell Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day AvenCell Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at AvenCell Therapeutics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
AvenCell Therapeutics
Location
Cambridge, Massachusetts, United States
About
AvenCell Therapeutics, Inc. is a leading clinical-stage cell therapy company that focuses on advancing autologous and allogeneic switchable CAR-T cell therapies. Their proprietary Universal Switchable CAR-T cell therapy platform is designed to treat various hematologic malignancies and autoimmune diseases. AvenCell aims to transform the standard of care with innovative and adaptable cell therapy treatments. The company has several pipeline candidates in clinical trials addressing high unmet medical needs.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AvenCell Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CambridgeBiotechnologyHealth CareMedicalTherapeutics